A landmark ruling by India’s high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec.

The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial interests.  Experts say it could embolden pharmaceutical companies in other countries hoping to produce generic versions of name-brand medications.  That could mean wider availability of the less expensive drugs throughout the … [Read More]

—–
Source: VOA News: Economy and Finance